Bioavailability of endomorphins and the blood-brain barrier-a review

Medicinal Chemistry

Volumn 10, Issue 1, 2014, Pages 2-17

  Perlikowska, Renata ^a   Janecka, Anna ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Analgesia; Bioavailability; Opioid peptides; Opioid receptors; Passive diffusion; Peptide permeability

Indexed keywords

CELL PENETRATING PEPTIDE; ENDORPHIN; LIPOSOME; OCTANOL; OPIATE; PEPTIDOMIMETIC AGENT;

BLOOD BRAIN BARRIER; CHEMICAL MODIFICATION; COMPUTER MODEL; CYCLIZATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG TRANSPORT; GLYCOSYLATION; HUMAN; NONHUMAN; PARTITION COEFFICIENT; PRIORITY JOURNAL; REVIEW;

ANALGESICS, OPIOID; BIOLOGICAL AVAILABILITY; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; HUMANS; MODELS, BIOLOGICAL; OLIGOPEPTIDES;

EID: 84891360918     PISSN: 15734064     EISSN: 18756638     Source Type: Journal    
DOI: 10.2174/15734064113099990040     Document Type: Review

References (130)

1. Vaccarino, A.L.; Kastin, A.J. Endogenous opiates: 2000. Peptides, 2001, 22, 2257-328.
2. Janecka, A.; Fichna, J.; Janecki, T. Opioid receptors and their ligands. Curr. Top. Med. Chem., 2004, 4, 1-17.
3. Gentilucci, L. New trends in the development of opioid peptide analogues as advanced remedies for pain relief. Curr. Top. Med. Chem., 2004, 4, 19-38.
4. Minnis, J.G.; Patierno, S.; Kohlmeier, S.E.; Brecha, N.C.; Tonini, M.; Sternini, C. Ligand-induced mu opioid receptor endocytosis and recycling in enteric neurons. Neurosci., 2003, 119, 33-42.
5. Zadina, J.E.; Hackler, L.; Ge, L.J.; Kastin, A.J. A potent and selective endogenous agonist for the mu-opiate receptor. Nature, 1997, 386, 499-502.
6. Hacker, L.; Zadina, J.E.; Ge, L.J.; Kastin, A.J. Isolation of relatively large amounts of endomorphin-1 and endomorphin-2 from human brain cortex. Peptides, 1997, 18, 1635-9.
7. Vaccarino, A.L.; Olson, G.A.; Olson, R.D.; Kastin, A.J. Endogenous opiates: 1998. Peptides, 1999, 20, 1527-74.
8. Wilson, A.M.; Soignier, R.D.; Zadina, J.E.; Kastin, A.J.; Nores, W.L.; Olson, R.D.; Olson, G.A. Dissociation of analgesic and rewarding effects of endomorphin-1 in rats. Peptides, 2000, 21, 1871-4.
9. Czapla, M.A.; Gozal, D.; Alea, O.A.; Beckerman, R.C.; Zadina, J.E. Differential cardiorespiratory effects of endomorphin 1 and endomorphin 2, DAMGO, and morphine. Am. J. Respir. Crit. Care Med., 2000, 162, 994-9.
10. Janecka, A.; Staniszewska, R.; Fichna, J. Endomorphin analogs. Curr. Med. Chem., 2007, 14, 3201-8.
11. Krol, S. Challenges in drug delivery to the brain: Nature is against us. J. Control. Release, 2012, 164, 145-55.
12. Oldendorf, W.H. Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection. Am. J. Physiol., 1971, 221, 1629-39.
13. Egleton, R.D.; Davis, T.P. Bioavailability and transport of peptides and peptide drugs into the brain. Peptides, 1997, 18, 1431-9.
14. Egleton, R.D.; Abbruscato, T.J.; Thomas, S.A.; Davis, T.P. Transport of opioid peptides into the central nervous system. J. Pharm. Sci., 1998, 87, 1433-9.
15. Begley, D.J.; Brightman, M.W. Structural and functional aspects of the blood-brain barrier. Prog. Drug Res., 2003, 61, 39-78.
16. Abbott, N.J.; Patabendige, A.A.; Dolman, D.E.; Yusof, S.R.; Begley, D.J. Structure and function of the blood-brain barrier. Neurobiol. Dis., 2010, 37, 13-25.
17. Hawkins, B.T.; Davis, T.P. The bloodbrain barrier/neurovascular unit in health and disease. Pharmacol. Rev., 2005, 57, 173-85.
18. Wilhelm, I.; Fazakas, C.; Krizbai, I.A. In vitro models of the bloodbrain barrier. Acta Neurobiol. Exp., 2011, 71, 113-28.
19. Liu, W.Y.; Wang, Z.B.; Zhang, L.C.; Wei, X.; Li, L. Tight junction in blood-brain barrier: an overview of structure, regulation, and regulator substances. CNS Neurosci. Ther., 2012, 18, 609-15.
20. Butt, A.M.; Jones, H.C.; Abbott, N.J. Electrical resistance across the blood-brain barrier in anaesthetized rats. J. Physiol. (London), 1990, 429, 47-62.
21. Pardridge, W.M. Drug transport across the blood-brain barrier. J. Cereb. Blood Flow Metab., 2012, 32, 1959-72.
22. Begley, D.J. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol. Ther., 2004, 104, 29-45.
23. Westholm, D.E.; Rumbley, J.N.; Salo, D.R.; Rich, T.P.; Anderson, G.W. Organic anion-transporting polypeptides at the blood-brain and blood-cerebrospinal fluid barriers. Curr. Top. Dev. Biol., 2008, 80, 135-70.
24. Oldendorf, W.H.; Cornford, M.E.; Brown, W.J. The large apparent work capability of the blood-brain barrier: a study of the mitochondrial content of capillary endothelial cells in brain and other tissues of the rat. Ann. Neurol., 1977, 1, 409-17.
25. De Vries, H.E.; Kuiper, J.; De Boer, A.G.; Van Berkel, T.J.; Breimer, D.D. The blood-brain barrier in neuroinflammatory diseases. Pharmacol. Rev., 1997, 49, 143-155.
26. Abbott, N.J. Dynamics of CNS barriers: evolution, differentiation, and modulation. Cell. Mol. Neurobiol., 2005, 25, 5-23.
27. Pardridge, W.M. Molecular biology of the blood-brain barrier. Mol. Biotechnol., 2005, 30, 57-70.
28. Pardridge, W.M. The blood-brain barrier: bottleneck in brain drug development. NeuroRx., 2005, 2, 3-14.
29. Chen, Y.; Liu, L. Modern methods for delivery of drugs across the blood-brain barrier. Adv. Drug Deliv. Rev., 2012, 64, 640-65.
30. Abbott, N.J.; Rönnbäck, L.; Hansson, E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci., 2006, 7, 41-53.
31. Brownlees, J.; Williams, C.H. Peptidases, peptides, and the mammalian blood-brain barrier. J. Neurochem., 1993, 60, 793-803.
32. Kastin, A.J.; Hahn, K.; Zadina, J.E. Regional differences in peptide degradation by rat cerebral microvessels: a potential novel regulatory mechanism for communication between blood and brain. Life Sci., 2001, 69, 1305-12.
33. Banks, W.A. Delivery of peptides to the brain: emphasis on therapeutic development. Biopolymers, 2008, 90, 589-94.
34. Banks, W.A. Characteristics of compounds that cross the bloodbrain barrier. BMC Neurol., 2009, 9, 1-5.
35. Hervé, F.; Ghinea, N.; Scherrmann, J.M. CNS delivery via adsorptive transcytosis. AAPS J., 2008, 10, 455-72.
36. Kastin, A.J.; Fasold, M.B.; Smith, R.R.; Horner, K.A.; Zadina, J.E. Saturable brain-to-blood transport of endomorphins. Exp. Brain Res., 2001, 139, 70-5.
37. Somogyvari-Vigh, A.; Kastin, A.J.; Liao, J.; Zadina, J.E.; Pan, W. Endomorphins exit the brain by a saturable efflux system at the basolateral surface of cerebral endothelial cells. Exp. Brain Res., 2004, 156, 224-30.
38. Allt, G.; Lawrenson, J.G. The blood-nerve barrier: enzymes, transporters and receptors-a comparison with the blood-brain barrier. Brain Res. Bull., 2000, 52, 1-12.
39. Oldendorf, W.H. Lipid solubility and drug penetration of the bloodbrain barrier. Proc. Soc. Exp. Biol. Med., 1974, 147, 813-16.
40. Ramaswami, V.; Haaseth, R.C.; Matsunaga, T.O.; Hruby, V.J.; O'Brien, D.F. Opioid peptide interactions with lipid bilayer membranes. Biochim. Biophys. Acta., 1992, 1109, 195-202.
41. Pauletti, G.M.; Gangwar, S.; Siahaan, T.J.; Aubé, J.; Burchardt, R.T. Improvement of oral peptide bioavailability: Peptidomimetics and prodrug strategies. Adv. Drug Deliv. Rev., 1997, 27, 235-56.
42. Weksler, B.B.; Subileau, E.A.; Perrière, N.; Charneau, P.; Holloway, K.; Leveque, M.; Tricoire-Leignel, H.; Nicotra, A.; Bourdoulous, S.; Turowski, P.; Male, D.K.; Roux, F.; Greenwood, J.; Romero, I.A.; Couraud, P.O. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J., 2005, 19, 1872-874.
43. Witt, K.A.; Gillespie, T.J.; Huber, J.D.; Egleton, R.D.; Davis, T.P. Peptide drug modifications to enhance bioavailability and bloodbrain barrier permeability. Peptides, 2001, 22, 2329-43.
44. Kastin, A.J.; Pan, W. Blood-brain barrier and feeding: regulatory roles of saturable transport systems for ingestive peptides. Curr. Pharm. Des., 2008, 14, 1615-9.
45. Polt, R.; Dhanasekaran, M.; Keyari, C.M. Glycosylated neuropeptides: a new vista for neuropsychopharmacology? Med. Res. Rev., 2005, 25, 557-85.
46. Ballet, S.; Misicka, A.; Kosson, P.; Lemieux, C.; Chung, N.N.; Schiller, P.W.; Lipkowski, A.W.; Tourwé, D. Blood-brain barrier penetration by two dermorphin tetrapeptide analogues: role of lipophilicity vs structural flexibility. J. Med. Chem., 2008, 51, 2571-4.
47. Dhanasekaran, M.; Polt, R. New prospects for glycopeptide based analgesia: glycoside-induced penetration of the blood-brain barrier. Curr. Drug Deliv., 2005, 2, 59-73.
48. Begley, D.J. The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system. J. Pharm. Pharmacol., 1996, 48, 136-46.
49. Dehring, K.A.; Workman, H.L.; Miller, K.D.; Mandagere, A.; Poole, S.K. Automated robotic liquid handling/laser-based nephelometry system for high throughput measurement of kinetic aqueous solubility. J. Pharm. Biomed. Anal., 2004, 36, 447-56.
50. Ganapathy, V.; Miyauchi, S. Transport systems for opioid peptides in mammalian tissues. AAPS J., 2005, 7, E852-6.
51. Van Dorpe, S.; Adriaens, A.; Polis, I.; Peremans, K.; Van Bocxlaer, J.; De Spiegeleer, B. Analytical characterization and comparison of the blood-brain barrier permeability of eight opioid peptides. Peptides, 2010, 31, 1390-9.
52. Kastin, A.J.; Akerstrom, V.; Pan, W.H. Interactions of glucagonlike peptide-1 (GLP-1) with the blood-brain barrier. J. Mol. Neurosci., 2002, 18, 7-14.
53. Peter, A.; Toth, G.; Tomboly, C.; Laus, G.; Tourwe, D. Liquid chromatographic study of the enzymatic degradation of endomorphins, with identification by electrospray ionization mass spectrometry. J. Chromatogr. A, 1999, 846, 39-48.
54. Tomboly, C.; Peter, A.; Toth, G. In vitro quantitative study of the degradation of endomorphins. Peptides, 2002, 23, 1573-80.
55. Janecka, A.; Staniszewska, R.; Gach, K.; Fichna, J. Enzymatic degradation of endomorphins. Peptides, 2008, 29, 2066-73.
56. Naik, P.; Cucullo, L. In vitro blood-brain barrier models: current and perspective technologies. J. Pharm. Sci., 2012, 101, 1337-54.
57. Liu, W.X.; Wang, R. Endomorphins: potential roles and therapeutic indications in the development of opioid peptide analgesic drugs. Med. Res. Rev., 2012, 32, 536-80.
58. Hansch, C.; Maloney, P.P.; Fujita, T. Correlation of biological activity of phenoxyacetic acids with hammett substituent constants and partition coefficients. Nature, 1962, 194, 178-80.
59. Hau, V.; Huber, J.D.; Campos, C.R.; Lipkowski, A.W.; Misicka, A.; Davis, T.P. Effect of guanidino modification and proline substitution on the in vitro stability and blood-brain barrier permeability of endomorphin II. J. Pharm. Sci., 2002, 91, 2140-9.
60. Liu, H.; Liu, X.; Yao, J.; Wang, C.; Yu, Y.; Wang, R. Utilization of combined chemical modifications to enhance the blood-brain barrier permeability and pharmacological activity of endomorphin-1. J. Pharmacol. Exp. Ther., 2006, 319, 308-16.
61. Liu, H.; Zhang, B.; Liu, X.; Wang, C.; Ni, J.; Wang, R. Endomorphin-1 analogs with enhanced metabolic stability and systemic analgesic activity: design, synthesis, and pharmacological characterization. Bioorg. Med. Chem., 2007, 15, 1694-702.
62. Lohmann, C.; Hüwel, S.; Galla, H.J. Predicting blood-brain barrier permeability of drugs: evaluation of different in vitro assays. J. Drug Target., 2002, 10, 263-76.
63. Sano, Y.; Shimizu, F.; Abe, M.; Maeda, T.; Kashiwamura, Y.; Ohtsuki, S.; Terasaki, T.; Obinata, M.; Kajiwara, K.; Fujii, M.; Suzuki, M.; Kanda, T. Establishment of a new conditionally immortalized human brain microvascular endothelial cell line retaining an in vivo blood-brain barrier function. J. Cell Physiol., 2010, 225, 519-28.
64. Trickler, W.J.; Lantz, S.M.; Murdock, R.C.; Schrand, A.M.; Robinson, B.L.; Newport, G.D.; Schlager, J.J.; Oldenburg, S.J.; Paule, M.G.; Slikker, W.Jr.; Hussain, S.M.; Ali, S.F. Silver nanoparticle induced blood-brain barrier inflammation and increased permeability in primary rat brain microvessel endothelial cells. Toxicol. Sci., 2010, 118, 160-70.
65. Roux, F.; Couraud, P.O. Rat brain endothelial cell lines for the study of blood-brain barrier permeability and transport functions. Cell Mol. Neurobiol., 2005, 25, 41-58.
66. Hakkarainen, J.J.; Pajander, J.; Laitinen, R.; Suhonen, M.; Forsberg, M.M. Similar molecular descriptors determine the in vitro drug permeability in endothelial and epithelial cells. Int. J. Pharm. 2012, 436, 426-43.
67. Volpe, D.A. Drug-permeability and transporter assays in Caco-2 and MDCK cell lines. Future Med. Chem., 2011, 3, 2063-77.
68. Man, S.; Ubogu, E.E.; Williams, K.A.; Tucky, B.; Callahan, M.K.; Ransohoff, R.M. Human brain microvascular endothelial cells and umbilical vein endothelial cells differentially facilitate leukocyte recruitment and utilize chemokines for T cell migration. Clin. Dev. Immunol., 2008, 2008, 384982.
69. Koda, Y.; Shiotani, K.; Toth, I.; Tsuda, Y.; Okada, Y.; Blanchfield, J.T. Comparison of the in vitro apparent permeability and stability of opioid mimetic compounds with that of the native peptide. Bioorg. Med. Chem. Lett., 2007, 17, 2043-6.
70. Koda, Y.; Del Borgo, M.; Wessling, S.T.; Lazarus, L.H.; Okada, Y.; Toth, I.; Blanchfield, J.T. Synthesis and in vitro evaluation of a library of modified endomorphin 1 peptides. Bioorg. Med. Chem., 2008, 16, 6286-96.
71. Koda, Y.; Liang, M.T.; Blanchfield, J.T.; Toth, I. In vitro stability and permeability studies of liposomal delivery systems for a novel lipophilic endomorphin 1 analogue. Int. J. Pharm., 2008, 356, 37-43.
72. Iwan, M.; Jarmolowska, B.; Bielikowicz, K.; Kostyra, E.; Kostyra, H.; Kaczmarski, M. Transport of mu-opioid receptor agonists and antagonist peptides across Caco-2 monolayer. Peptides, 2008, 29, 1042-7.
73. Ades, E.W.; Candal, F.J.; Swerlick, R.A.; George, V.G.; Summers, S.; Bosse, D.C.; Lawley, T.J. HMEC-1: Establishment of an immortalized human microvascular endothelial cell line. J. Invest. Dermatol., 1992, 99, 683-90.
74. Bickel, U. How to measure drug transport across the blood-brain barrier. NeuroRx., 2005, 2(1), 15-26.
75. Di, L.; Kerns, E.H.; Bezar, I.F.; Petusky, S.L.; Huang, Y. Comparison of blood-brain barrier permeability assays: in situ brain perfusion, MDR1-MDCKII and PAMPA-BBB. J. Pharm. Sci., 2009, 98, 1980-91.
76. Lu, J. A novel hypothesis of blood-brain barrier (BBB) development and in vitro BBB model: neural stem cell is the driver of BBB formation and maintenance. J. Exp. Integr. Med., 2012, 2, 39-43.
77. Hutamekalin, P.; Farkas, A.E.; Orbok, A.; Wilhelm, I.; Nagyoszi, P.; Veszelka, S.; Deli, M.A.; Buzas, K.; Hunyadi-Gulyas, E.; Medzihradszky, K.F.; Meksuriyen, D.; Krizbai, I.A. Effect of nicotine and polyaromtic hydrocarbons on cerebral endothelial cells. Cell Biol. Int., 2008, 32, 198-209.
78. Fazakas, C.; Wilhelm, I.; Nagyoszi, P.; Farkas, A.E.; Hasko, J.; Molnar, J.; Bauer, H.; Bauer, H.C.; Ayaydin, F.; Dung, N.T.; Siklos, L.; Krizbai, I.A. Transmigration of melanoma cells through the blood-brain barrier: role of endothelial tight junctions and melanoma-released serine proteases. PLoS One, 2011, 6, e20758.
79. Sziraki, I.; Erdo, F.; Beery, E.; Molnar, P.M.; Fazakas, C.; Wilhelm, I.; Makai, I.; Kis, E.; Heredi-Szabo, K.; Abonyi, T.; Krizbai, I.; Toth, G.K.; Krajcsi, P. Quinidine as an ABCB1 probe for testing drug interactions at the blood-brain barrier: an in vitro in vivo correlation study. J. Biomol. Screen., 2011, 16, 886-94.
80. Deli, M.A.; Abrahám, C.S.; Kataoka, Y.; Niwa, M. Permeability studies on in vitro blood-brain barrier models: physiology, pathology, and pharmacology. Cell Mol. Neurobiol., 2005, 25, 59-127.
81. Thomas, S.A.; Abbruscato, T.J.; Hau, V.S.; Gillespie, T.J.; Zsigo, J.; Hruby, V.J.; Davis, T.P. Structure-activity relationships of a series of [D-Ala2]deltorphin I and II analogues; in vitro blood-brain barrier permeability and stability. J. Pharmacol. Exp. Ther., 1997, 281, 817-25.
82. Weber, S.J.; Abbruscato, T.J.; Brownson, E.A.; Lipkowski, A.W.; Polt, R.; Misicka, A.; Haaseth, R.C.; Bartosz, H.; Hruby, V.J.; Davis, T.P. Assessment of an in vitro blood-brain barrier model using several [Met5]enkephalin opioid analogs. J. Pharmacol. Exp. Ther., 1993, 266, 1649-55.
83. Cucullo, L.; Marchi, N.; Hossain, M.; Janigro, D. A dynamic in vitro BBB model for the study of immune cell trafficking into the central nervous system. J. Cereb. Blood Flow. Metab., 2011, 31, 767-77.
84. Santaguida, S.; Janigro, D.; Hossain, M.; Oby, E.; Rapp, E.; Cucullo, L. Side by side comparison between dynamic versus static models of blood-brain barrier in vitro: a permeability study. Brain Res., 2006, 1109, 1-13.
85. Mallaredy, J.R.; Toth, G.; Fazakas, C.; Molnar, J.; Nagyoszi, P.; Lipkowski, A.W.; Krizbai, I.A.; Wilhelm I. Transport characteristics of endomorphin-2 analogues in brain capillary endothelial cells. Chem. Biol. Drug Des., 2012, 79, 507-13.
86. Smith, Q.R. Brain perfusion systems for studies of drug uptake and metabolism in the central nervous system. Pharm. Biotechnol., 1996, 8, 285307.
87. Temsamani, J.; Scherrmann, J.M.; Rees, A.R.; Kaczorek, M. Brain drug delivery technologies: novel approaches for transporting therapeutics. Pharm. Sci. Technolo. Today, 2000, 3, 155-62.
88. Witt, K.A.; Davis, T.P. CNS drug delivery: opioid peptides and the blood-brain barrier. AAPS J., 2006, 8, E76-88.
89. Kruszynski, R.; Fichna, J.; do-Rego, J.C.; Janecki, T.; Kosson, P.; Pakulska, W.; Costentin, J.; Janecka, A. Synthesis and biological activity of N-methylated analogs of endomorphin-2. Bioorg. Med. Chem., 2005, 13, 6713-7.
90. Li, T.; Fujita, Y.; Tsuda, Y.; Miyazaki, A.; Ambo, A.; Sasaki, Y.; Jinsmaa, Y.; Bryant, S.D.; Lazarus, L.H.; Okada, Y. Development of potent mu-opioid receptor ligands using unique tyrosine analogues of endomorphin-2. J. Med. Chem., 2005, 48, 586-92.
91. Janecka, A.; Kruszynski, R. Conformationally restricted peptides as tools in opioid receptor studies. Curr. Med. Chem., 2005, 12, 471-81.
92. Gentry, C.L.; Egleton, R.D.; Gillespie, T.; Abbruscato, T.J.; Bechowski, H.B.; Hruby, V.J.; Davis, T.P. The effect of halogenation on blood-brain barrier permeability of a novel peptide drug. Peptides, 1999, 20, 1229-38.
93. Varamini, P.; Mansfeld, F.M.; Blanchfield, J.T.; Wyse, B.D.; Smith, M.T.; Toth, I. Lipo-endomorphin-1 derivatives with systemic activity against neuropathic pain without producing constipation. PLoS One, 2012, 7, e41909.
94. Varamini, P.; Hussein, W.M.; Mansfeld, F.M.; Toth I. Synthesis, biological activity and structure-activity relationship of endomorphin-1/ substance P derivatives. Bioorg. Med. Chem., 2012, 20, 6335-43.
95. Kumagai, A.K.; Eisenberg, J.B.; Pardridge, W.M. Absorptivemediated endocytosis of cationized albumin and a beta-endorphincationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport. J. Biol. Chem., 1987, 262, 15214-9.
96. Ogawa, T.; Miyamae, T.; Murayama, K.; Okuyama, K.; Okayama, T.; Hagiwara, M.; Sakurada, S.; Morikawa, T. Synthesis and structure-activity relationships of an orally available and long-acting analgesic peptide, N(alpha)-amidino-Tyr- D-Arg-Phe-MebetaAla-OH (ADAMB). J. Med. Chem., 2002, 45, 5081-89.
97. Lis, H.; Sharon N. Protein glycosylation. Structural and functional aspects. Eur. J. Biochem., 1993, 218, 1-27.
98. Polt, R.; Porreca, F.; Szabo, L.Z.; Bilsky, E.J.; Davis, P.; Abbruscato, T.J.; Davis, T.P.; Harvath, R.; Yamamura, H.I.; Hruby, V.J. Glycopeptide enkephalin analogues produce analgesia in mice: evidence for penetration of the blood-brain barrier. Proc. Natl. Acad. Sci. U S A, 1994, 91, 7114-8.
99. Egleton, R.D.; Mitchell, S.A.; Huber, J.D.; Janders, J.; Stropova, D.; Polt, R.; Yamamura, H.I.; Hruby, V.J.; Davis, T.P. Improved bioavailability to the brain of glycosylated Met-enkephalin analogs. Brain Res., 2000, 881, 37-46.
100. Palian, M.M.; Polt, R.L. Glycopeptide analgesics. Drug. Future, 2001, 26, 561-76.
101. Bilsky, E.J.; Egleton, R.D.; Mitchell, S.A.; Palian, M.M.; Davis, P.; Huber, J.D.; Jones, H.; Yamamura, H.I.; Janders, J.; Davis, T.P.; Porreca, F.; Hruby, V.J.; Polt, R. Enkephalin glycopeptide analogues produce analgesia with reduced dependence liability. J. Med. Chem., 2000, 43, 2586-90.
102. Tomatis, R.; Marastoni, M.; Balboni, G.; Guerrini, R.; Capasso, A.; Sorrentino, L.; Santagada, V.; Caliendo, G.; Lazarus, L.H.; Salvadori, S. Synthesis and pharmacological activity of deltorphin and dermorphin-related glycopeptides. J. Med. Chem., 1997, 40, 2948-52.
103. Negri, L.; Lattanzi, R.; Tabacco, F.; Orru, L.; Severini, C.; Scolaro, B.; Rocchi, R. Dermorphin and deltorphin glycosylated analogues: synthesis and antinociceptive activity after systemic administration. J. Med. Chem., 1999, 42, 400-4.
104. Bardají, E.; Torres, J.L.; Clapés, P.; Albericio, F.; Barany, G.; Rodríguez, R.E., Sacristán, M.P.; Valencia, G. Synthesis and biological activity of O-glycosylated morphiceptin analogues. J. Chem. Soc. Perkin Trans., 1991, 1, 1755-9.
105. Biondi, B.; Giannini, E.; Negri, L.; Melchiorri, P.; Lattanzi, R.; Rosso, F.; Ciocca, L.; Rocchi, R. Opioid peptides: Synthesis and biological activity of new endomorphin analogues. Int. J. Pept. Res. Ther., 2006, 12, 145-51.
106. Varamini, P.; Mansfeld, F.M.; Blanchfield, J.T.; Wyse, B.D.; Smith, M.T.; Toth, I. Synthesis and biological evaluation of an orally active glycosylated endomorphin-1. J. Med. Chem., 2012, 55, 5859-67.
107. Schiller, P.W.; Fundytus, M.E.; Merovitz, L.; Weltrowska, G.; Nguyen, T.M.; Lemieux, C.; Chung, N.N.; Coderre, T.J. The opioid mu agonist/delta antagonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats. J. Med. Chem., 1999, 42, 3520-6.
108. Hruby, V.J.; Balse, P.M. Conformational and topographical considerations in designing agonist peptidomimetics from peptide leads. Curr. Med. Chem., 2000, 7, 945-70.
109. Davies, J.S. The cyclization of peptides and depsipeptides. J. Peptide Sci., 2003, 9, 471-501.
110. Cardillo, G.; Gentilucci, L.; Tolomelli, A.; Spinosa, R.; Calienni, M.; Qasem, A.R.; Spampinato, S. Synthesis and evaluation of the affinity toward mu-opioid receptors of atypical, lipophilic ligands based on the sequence c[-Tyr-Pro-Trp-Phe-Gly-]. J. Med. Chem., 2004, 47, 5198-203.
111. Gentilucci, L.; Squassabia, F.; Demarco, R.; Artali, R.; Cardillo, G.; Tolomelli, A.; Spampinato, S.; Bedini, A. Investigation of the interaction between the atypical agonist c[YpwFG] and MOR. FEBS J., 2008, 275, 2315-37.
112. Bedini, A.; Baiula, M.; Gentilucci, L.; Tolomelli, A.; De Marco, R.; Spampinato, S. Peripheral antinociceptive effects of the cyclic endomorphin-1 analog c[YpwFG] in a mouse visceral pain model. Peptides, 2010, 31, 2135-40.
113. Gentilucci, L.; Tolomelli, A.; De Marco R, Spampinato S, Bedini A, Artali R. The inverse type II β-turn on D-Trp-Phe, a pharmacophoric motif for MOR agonists. Chem. Med. Chem., 2011, 6, 1640-53.
114. Perlikowska, R.; Do-Rego, J.C.; Cravezic, A.; Fichna, J.; Wyrebska, A.; Toth, G.; Janecka, A. Synthesis and biological evaluation of cyclic endomorphin-2 analogs. Peptides, 2010, 31, 339-45.
115. Fichna, J.; Perlikowska, R.; Wyrebska, A.; Gach, K.; Piekielna, J.; Do-Rego, J.C.; Toth, G.; Kluczyk, A.; Janecki, T.; Janecka, A. Effect of 2',6'-dimethyl-L-tyrosine (Dmt) on pharmacological activity of cyclic endomorphin-2 and morphiceptin analogs. Bioorg. Med. Chem., 2011, 19, 6977-81.
116. Adessi, C.; Soto, C. Converting a peptide into a drug: strategies to improve stability and bioavailability. Curr. Med. Chem., 2002, 9, 963-78.
117. Okada, Y.; Tsuda, Y.; Fujita, Y.; Yokoi, T.; Sasaki, Y.; Ambo, A.; Konishi, R.; Nagata, M.; Salvadori S.; Jinsmaa, Y.; Bryant, S.D.; Lazarus, L.H. Unique high-affinity synthetic mu-opioid receptor agonists with central- and systemic-mediated analgesia. J. Med. Chem., 2003, 46, 3201-9.
118. Jinsmaa, Y.; Miyazaki, A.; Fujita, Y.; Li, T.; Fujisawa, Y.; Shiotani, K.; Tsuda, Y.; Yokoi, T.; Ambo, A.; Sasaki, Y.; Bryant, S.D., Lazarus, L.H., Okada, Y. Oral bioavailability of a new class of micro-opioid receptor agonists containing 3,6-bis[Dmt-NH(CH2)n]-2(1H)-pyrazinone with central-mediated analgesia. J. Med. Chem., 2004, 47, 2599-610.
119. Okada, Y.; Tsuda, Y.; Salvadori, S.; Lazarus, LH. Developmental potential for endomorphin opioidmimetic drugs. Int. J. Med. Chem., 2012, doi:10.1155/2012/715123.
120. Patel, L.N.; Zaro, J.L.; Shen, W.C. Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives. Pharm. Res., 2007, 24, 1977-92.
121. Temsamani, J.; Vidal, P. The use of cell-penetrating peptides for drug delivery. Drug Discov. Today, 2004, 9, 1012-9.
122. Rousselle, C.; Clair, P.; Smirnova, M.; Kolesnikov, Y.; Pasternak, G.W.; Gac-Breton, S.; Rees, A.R.; Scherrmann, J.M.; Temsamani, J. Improved brain uptake and pharmacological activity of dalargin using a peptide-vector-mediated strategy. J. Pharmacol. Exp. Ther., 2003, 306, 371-6.
123. Yu, Y.; Shao, X.; Cui, Y.; Liu, H.M.; Wang, C.L.; Fan, Y.Z.; Liu, J.; Dong, S.L.; Cui, Y.X.; Wang, R. Structure-activity study on the spatial arrangement of the third aromatic ring of endomorphins 1 and 2 using an atypical constrained C terminus. Chem. Med. Chem., 2007, 2, 309-17.
124. Wang, C.L.; Guo, C.; Wang, Y.Q.; Zhou, Y.; Li, Q.; Ni, J.M.; Wang, R. Synthesis and antinociceptive effects of endomorphin-1 analogs with C-terminal linked by oligoarginine. Peptides, 2011, 32, 293-9.
125. Maysinger, D.; Morinville, A. Drug delivery to the nervous system. Trends Biotechnol., 1997, 15, 410-8.
126. Forssen, E.; Willis, M. Ligand-targeted liposomes. Adv. Drug Deliv. Rev., 1998, 29, 249-71.
127. Fahr, A.; Van Hoogevest, P.; May, S.; Bergstrand, N.; Leigh, M.L.S. Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery. Eur. J. Pharm. Sci., 2005, 26, 251-65.
128. Storm, G.; Crommelin, D.J.A. Liposomes: quo vadis? PSTT, 1998, 1, 19-31.
129. Liang, M.T.; Davies, N.M.; Toth, I. Encapsulation of lipopeptides within liposomes: effect of number of lipid chains, chain length and method of liposome preparation. Int. J. Pharm., 2005, 301, 247-54.
130. Bao, H.; Jin, X.; Li, L.; Lv, F.; Liu, T. OX26 modified hyperbranched polyglycerol-conjugated poly(lactic-co-glycolic acid) nanoparticles: synthesis, characterization and evaluation of its brain delivery ability. J. Mater Sci. Mater Med., 2012, 23, 1891-901.